Literature DB >> 24931450

The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis.

Elizabeth K Stranks1, Simon F Crowe.   

Abstract

The "z-drugs" zopiclone, zolpidem, eszopiclone, and zaleplon were introduced in the 1980s for the treatment of insomnia, as it was observed that the side effect profile associated with these medications were more benign than those related to the benzodiazepines. This meta-analysis set out to ascertain which domains of cognitive function, if any, were affected by the ingestion of these medications. A total of 20 studies met the study inclusion criteria. Results revealed medium effect sizes for zopiclone and zolpidem on measures of verbal memory. An additional medium effect size was observed for zolpidem on attention. Finally, smaller effect sizes were observed for zolpidem speed of processing and for zopiclone on working memory. It is clear from these data that the use of a single dose of the z-drugs in healthy adults as measured in the morning following the exposure does produce a specific rather than a generalized negative effect on cognitive function. However, there were only enough studies to evaluate the individual cognitive effects of the zolpidem and zopiclone medications; the specific effects of zaleplon and eszopiclone cannot be ascertained because only one study met the inclusion and exclusion criteria for the review.

Entities:  

Keywords:  Cognitive effects; Eszopiclone; Meta-analysis; Zaleplon; Zolpidem; Zopiclone

Mesh:

Substances:

Year:  2014        PMID: 24931450     DOI: 10.1080/13803395.2014.928268

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  19 in total

1.  Optical probing of orexin/hypocretin receptor antagonists.

Authors:  Shi-Bin Li; Natalie Nevárez; William J Giardino; Luis de Lecea
Journal:  Sleep       Date:  2018-10-01       Impact factor: 5.849

Review 2.  Zolpidem: Efficacy and Side Effects for Insomnia.

Authors:  Amber N Edinoff; Natalie Wu; Yahya T Ghaffar; Rosemary Prejean; Rachel Gremillion; Mark Cogburn; Azem A Chami; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-18

3.  State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Authors:  Robert W Gould; Michael T Nedelcovych; Xuewen Gong; Erica Tsai; Michael Bubser; Thomas M Bridges; Michael R Wood; Mark E Duggan; Nicholas J Brandon; John Dunlop; Michael W Wood; Magnus Ivarsson; Meredith J Noetzel; J Scott Daniels; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  Neuropharmacology       Date:  2015-11-23       Impact factor: 5.250

Review 4.  [Neurocognitive disorders in old age : Role of pharmacotherapy in prevention and treatment].

Authors:  J Pantel
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

Review 5.  Insomnia in the Military: Application and Effectiveness of Cognitive and Pharmacologic Therapies.

Authors:  Vincent F Capaldi; Jessica R Kim; Antigone A Grillakis; Maura R Taylor; Carla M York
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

Review 6.  Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Taro Kishi; Shinji Matsunaga; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-06-18       Impact factor: 5.270

Review 7.  The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature.

Authors:  Rebecca B Costello; Cynthia V Lentino; Courtney C Boyd; Meghan L O'Connell; Cindy C Crawford; Meredith L Sprengel; Patricia A Deuster
Journal:  Nutr J       Date:  2014-11-07       Impact factor: 3.271

Review 8.  Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit.

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2016-05-19

9.  An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study.

Authors:  Hsin-I Shih; Che-Chen Lin; Yi-Fang Tu; Chia-Ming Chang; Hsiang-Chin Hsu; Chih-Hsien Chi; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

10.  Interrupted Time Series Analysis of Changes in Zolpidem Use Due to Media Broadcasts.

Authors:  Bo-Ram Yang; Kyu-Nam Heo; Yun Mi Yu; Ga-Bin Yeom; Hye Duck Choi; Ju-Yeun Lee; Young-Mi Ah
Journal:  Int J Environ Res Public Health       Date:  2021-05-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.